Psychedelic and ketamine research trials in Mexico

Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.

5 registered studies are counted in Mexico. By compound: 5 ketamine. By registry status: 2 completed and 3 status not reported. By phase: 1 phase 1, 1 phase 2, 2 phase 3 and 1 phase 4. Reported start years run from 2013 (earliest) to 2020 (latest). Studies are linked to 4 institutions.

Country is taken from the research site linked to each registry record. A study counts once, and a study tagged with more than one compound is counted under each compound. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.

Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.

Recruiting now

None of the 5 counted studies in Mexico is listed in the registry as recruiting or not yet recruiting as of 11 October 2026. Status is reported by study teams and can be out of date.

At a glance

5 registered studies are counted on this page.

By compound

Compound hub	Studies
Ketamine	5

By registry status

Status	Studies	Share
Completed	2	40%
Status not reported	3	60%

By phase

Phase	Studies	Share
Phase 1	1	20%
Phase 2	1	20%
Phase 3	2	40%
Phase 4	1	20%

When studies started

Start year	Studies
2020 to 2023	1
2015 to 2019	2
2010 to 2014	2

All counted studies

All 5 counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.

Title as registered	Registry ID	Status	Phase	Start	Institution and city
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives	NCT04476446	Completed	Phase 3	2020-09-08	Janssen-Cilag, S.A., Guadalajara
Ketamine or Placebo in Patients With Major Depression and Advanced Cancer	NCT04471818	Completed	Phase 1	2019-09-19	Instituto Nacional de Cancerologia de Mexico, Mexico City
Evaluation of Schemes of Administration of Intravenous Ketamine in Depression	NCT03742557	Status not reported	Phase 3	2018-10-01	National Institute of Neurology and Neurosurgery, Mexico, Mexico City
Clinical Trial of the Use of Ketamine in Treatment Resistant Depression	NCT02610712	Status not reported	Phase 4	2014-05-01	National Institute of Neurology and Neurosurgery, Mexico, Mexico City
Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population	NCT01868802	Status not reported	Phase 2	2013-09-01	American British Cowdray Medical Center, Mexico City

About this data

Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.

Substance hubs for these compounds

Ketamine

Condition hubs

Condition hubs that include studies counted in this country, with the number of those studies. Conditions are matched by keyword on registered titles, so one study can appear under more than one condition.

Condition hub	Studies in this country
Depression	5
Treatment-resistant depression	4
Cancer and end-of-life distress	1

Other country hubs

All trial hubs | Learn | Disclaimer